Prostate Adenocarcinoma

Oncology·MeSH: Prostatic Neoplasms

Prevalence

5.0 / 100K

11 drugs in development·4 companies·27 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
Bicalutamide	ARS Pharmaceuticals, Inc. (SPRY)
Flutamide	ARS Pharmaceuticals, Inc. (SPRY)
Nilutamide	ARS Pharmaceuticals, Inc. (SPRY)

Phase 2(7)

Drug	Company
Degarelix	ARS Pharmaceuticals, Inc. (SPRY)
etrumadenant	Arcus Biosciences, Inc. (RCUS)
Goserelin Acetate	ARS Pharmaceuticals, Inc. (SPRY)
Leuprolide Acetate	ARS Pharmaceuticals, Inc. (SPRY)
Leuprolide Acetate	ENANTA PHARMACEUTICALS INC (ENTA)
Relugolix	KYNTRA BIO INC. (KYNB)
Tocilizumab	Arcus Biosciences, Inc. (RCUS)

Phase 4(1)

Drug	Company
Darolutamide 300 mg tablets	KYNTRA BIO INC. (KYNB)

BioSniper tracks 11 drugs in development for Prostate Adenocarcinoma across 4 companies.

There are 27 clinical trials targeting Prostate Adenocarcinoma tracked by BioSniper.

The estimated prevalence of Prostate Adenocarcinoma is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.